The emerging role of ctDNA in liver cancer management

David Pinato, MD, PhD, Imperial College London, London, UK, discusses the potential of circulating tumor DNA (ctDNA) as a biomarker for diagnosing and monitoring hepatocellular carcinoma (HCC). Tumor-released variants in ctDNA can provide information on disease activity. In HCC, ctDNA can help identify patients who may be curable and have a lower risk of relapse. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.